Previous 10 | Next 10 |
Companies targeting the monkeypox virus are on the rise in the pre-market Thursday as an Emergency Committee of the World Health Organization (WHO) meets today to decide whether to declare the latest outbreak a public health emergency of international concern. PHEIC designation is WHO's ...
Co-Diagnostics has an interesting vertical assay menu that has long-term upside potential. The company is profitable and adheres to the profitability metrics we see currently are driving equity returns. We price the stock at $11–$13.80 based on a blend of inputs, suggesting...
Co-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference PR Newswire SALT LAKE CITY , June 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a uniq...
Co-Diagnostics, Inc. to Host Booth at MEDEXPO Africa 2022 in Nairobi, Kenya on June 9-11 PR Newswire SALT LAKE CITY , June 9, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a uniq...
Becton, Dickinson and Company (NYSE:BDX) and CerTest Biotec, a European diagnostic device maker, announced a collaboration on Wednesday to develop a molecular diagnostic test for the Monkeypox virus. The assay will be available for the users of Becton’s (BDX) BD MAX System, an automate...
The shares of Co-Diagnostics (NASDAQ:CODX) are trading higher for the third straight session on Friday in solidarity with makers of monkeypox vaccines and therapeutics after molecular diagnostics company announced its contribution to address the virus outbreak. Co-Diagnostics (CODX) said Thur...
Investors took the measure of healthcare testing products specialist Co-Diagnostics (NASDAQ: CODX) and gave it an enthusiastic thumbs-up on Thursday: The company's stock closed the session more than 7% higher. That far outpaced the S&P 500 index's 2% gain on the day. The...
Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus PR Newswire SALT LAKE CITY , May 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, pa...
Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26 PR Newswire SALT LAKE CITY , May 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics com...
Co-Diagnostics, Inc. (CODX) Q1 2022 Earnings Conference Call May 12, 2022, 16:30 ET Company Participants Andrew Benson - Head, IR Dwight Egan - Chairman, CEO & President Brian Brown - CFO & Company Secretary Conference Call Participants Yi Chen - H.C. Wainwright & Co. James Sidoti...
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago PR Newswire SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company wi...
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developme...
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States PR Newswire SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company w...